Content Analysis: The increasing popularity of GLP-1 CNBC's Meg Tirrell and David Ricks, Exclusive Days after launching its
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
Eli Lilly
Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product
Eli Lilly CEO
Eli Lilly CEO on Fighting Obesity, Developing New Drugs
Eli Lilly
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
(0:00) Introducing
Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result
CNBC's Angelica Peebles and
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
The increasing popularity of GLP-1
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Dave Ricks, the
Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs
CNBC's Meg Tirrell and David Ricks,
Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
Eli Lilly
Exclusive | Eli Lilly CEO Dave Ricks On New Weight Loss Drug 'Mounjaro' | Global Dialogues
Exclusive | Days after launching its
Eli Lilly Is Working on an Anti-Obesity Pill, Says CEO Dave Ricks
Eli Lilly
Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro
Eli Lilly
Eli Lilly CEO: Our pill supply can 'reach the planet'
Eli Lilly
